MEI Pharma (MEIP) Stock Analysis

What MEI Pharma does

MEI Pharma, Inc. is a late-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for various cancers. Its robust pipeline features several key assets: Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor, is currently in a Phase III clinical trial for relapsed/refractory follicular lymphoma and a Phase Ib multi-arm study targeting B-cell malignancies. Additionally, Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, is undergoing Phase Ib clinical trials for acute myeloid leukemia and other B-cell malignancies. The company is also advancing ME-344, a mitochondrial inhibitor that targets the oxidative phosphorylation complex, through Phase I development for HER2-negative breast cancer. Completing its portfolio is Pracinostat, an orally administered histone deacetylase inhibitor, which is being evaluated in a Phase II clinical trial for myelodysplastic syndrome. MEI Pharma has forged strategic collaborations, including comprehensive license, development, and commercialization agreements with Kyowa Kirin Company and Helsinn Healthcare SA (the latter also encompassing manufacturing). It further holds a clinical collaboration with BeiGene, Ltd. and a licensing agreement with Presage Biosciences, Inc. Founded in 2000 as Marshall Edwards, Inc., the company rebranded to MEI Pharma, Inc. in July 2012 and maintains its corporate headquarters in San Diego, California.

Key metrics

ETFs linked to MEIP

Broad-market and Healthcare sector ETFs an investor holding MEI Pharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how MEIP fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for MEI Pharma?

MEI Pharma trades under the ticker MEIP on NASDAQ.

Which exchange is MEIP listed on?

MEIP is listed on NASDAQ.

What sector does MEI Pharma operate in?

MEI Pharma is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze MEIP in a portfolio?

PortView shows MEIP's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.